PEMBROLIZUMAB PLUS CHEMOTHERAPY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER

Javier Cortes and his research team have conducted a clinical trial, currently in phase 3, to study the effect of adding pembrolizumab to standard chemotherapy in patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more. The results show that the addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival than chemotherapy alone.

Download the news